Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications: a prospective feasibility study

Sanne Werner Møller Andersen; Camilla Ottesen; Klaus Gotfredsen; Simon Storgård Jensen; Thomas Kofod; Morten Schiodt

doi:10.1007/s10006-022-01042-5

Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications: a prospective feasibility study

Sanne Werner Møller Andersen, Camilla Ottesen, Klaus Gotfredsen, Simon Storgård Jensen, Thomas Kofod, Morten Schiodt

Research output: Contribution to journal › Journal article › Research › peer-review

5 Citations (Scopus)

Abstract

PURPOSE: Implant placement in patients with cancer receiving high-dose antiresorptive medication (HDAR) is considered contraindicated. This prospective, feasibility study tested the hypothesis that dental implants can be placed in such patients by applying a staged implant placement protocol with submerged healing.

METHODS: Three groups of patients on HDAR were included as follows: group 1: patients who underwent tooth extraction, without the development of medication-related osteonecrosis of the jaws (MRONJ); group 2: patients with surgically treated MRONJ who had demonstrated clinical healing for at least 3 months; group 3: patients with established MRONJ who was planned for surgical resection and simultaneous implant placement.

RESULTS: A total of 49 implants were placed in 27 patients (group 1: 12, group 2: 7 and group 3: 8). HDAR included bisphosphonates and denosumab. The mean HDAR time was 25 months (SD: ± 18.4, range 3-68 months). An abutment operation was performed 4 months following the implant placement (SD: ± 1.9, range 3-14 months). All patients healed uneventfully.

CONCLUSIONS: This study demonstrated that it is feasible to insert dental implants and perform an abutment surgery in patients with cancer on HDAR, without the development of MRONJ.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04741906.

Original language	English
Journal	Oral and Maxillofacial Surgery
Volume	27
Issue number	1
Pages (from-to)	89-100
Number of pages	12
ISSN	1865-1550
DOIs	https://doi.org/10.1007/s10006-022-01042-5
Publication status	Published - 2023

Bibliographical note

Access to Document

10.1007/s10006-022-01042-5

Cite this

Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications : a prospective feasibility study. / Andersen, Sanne Werner Møller; Ottesen, Camilla ; Gotfredsen, Klaus ; Jensen, Simon Storgård; Kofod, Thomas; Schiodt, Morten.

In: Oral and Maxillofacial Surgery, Vol. 27, No. 1, 2023, p. 89-100.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{5fbdb6d183ae406cbf7e6af20fc3f54f,

title = "Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications: a prospective feasibility study",

abstract = "PURPOSE: Implant placement in patients with cancer receiving high-dose antiresorptive medication (HDAR) is considered contraindicated. This prospective, feasibility study tested the hypothesis that dental implants can be placed in such patients by applying a staged implant placement protocol with submerged healing.METHODS: Three groups of patients on HDAR were included as follows: group 1: patients who underwent tooth extraction, without the development of medication-related osteonecrosis of the jaws (MRONJ); group 2: patients with surgically treated MRONJ who had demonstrated clinical healing for at least 3 months; group 3: patients with established MRONJ who was planned for surgical resection and simultaneous implant placement.RESULTS: A total of 49 implants were placed in 27 patients (group 1: 12, group 2: 7 and group 3: 8). HDAR included bisphosphonates and denosumab. The mean HDAR time was 25 months (SD: ± 18.4, range 3-68 months). An abutment operation was performed 4 months following the implant placement (SD: ± 1.9, range 3-14 months). All patients healed uneventfully.CONCLUSIONS: This study demonstrated that it is feasible to insert dental implants and perform an abutment surgery in patients with cancer on HDAR, without the development of MRONJ.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04741906.",

author = "Andersen, {Sanne Werner M{\o}ller} and Camilla Ottesen and Klaus Gotfredsen and Jensen, {Simon Storg{\aa}rd} and Thomas Kofod and Morten Schiodt",

note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2023",

doi = "10.1007/s10006-022-01042-5",

language = "English",

volume = "27",

pages = "89--100",

journal = "Mund-, Kiefer- und Gesichtschirurgie : MKG",

issn = "1865-1550",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications

T2 - a prospective feasibility study

AU - Andersen, Sanne Werner Møller

AU - Ottesen, Camilla

AU - Gotfredsen, Klaus

AU - Jensen, Simon Storgård

AU - Kofod, Thomas

AU - Schiodt, Morten

PY - 2023

Y1 - 2023

N2 - PURPOSE: Implant placement in patients with cancer receiving high-dose antiresorptive medication (HDAR) is considered contraindicated. This prospective, feasibility study tested the hypothesis that dental implants can be placed in such patients by applying a staged implant placement protocol with submerged healing.METHODS: Three groups of patients on HDAR were included as follows: group 1: patients who underwent tooth extraction, without the development of medication-related osteonecrosis of the jaws (MRONJ); group 2: patients with surgically treated MRONJ who had demonstrated clinical healing for at least 3 months; group 3: patients with established MRONJ who was planned for surgical resection and simultaneous implant placement.RESULTS: A total of 49 implants were placed in 27 patients (group 1: 12, group 2: 7 and group 3: 8). HDAR included bisphosphonates and denosumab. The mean HDAR time was 25 months (SD: ± 18.4, range 3-68 months). An abutment operation was performed 4 months following the implant placement (SD: ± 1.9, range 3-14 months). All patients healed uneventfully.CONCLUSIONS: This study demonstrated that it is feasible to insert dental implants and perform an abutment surgery in patients with cancer on HDAR, without the development of MRONJ.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04741906.

AB - PURPOSE: Implant placement in patients with cancer receiving high-dose antiresorptive medication (HDAR) is considered contraindicated. This prospective, feasibility study tested the hypothesis that dental implants can be placed in such patients by applying a staged implant placement protocol with submerged healing.METHODS: Three groups of patients on HDAR were included as follows: group 1: patients who underwent tooth extraction, without the development of medication-related osteonecrosis of the jaws (MRONJ); group 2: patients with surgically treated MRONJ who had demonstrated clinical healing for at least 3 months; group 3: patients with established MRONJ who was planned for surgical resection and simultaneous implant placement.RESULTS: A total of 49 implants were placed in 27 patients (group 1: 12, group 2: 7 and group 3: 8). HDAR included bisphosphonates and denosumab. The mean HDAR time was 25 months (SD: ± 18.4, range 3-68 months). An abutment operation was performed 4 months following the implant placement (SD: ± 1.9, range 3-14 months). All patients healed uneventfully.CONCLUSIONS: This study demonstrated that it is feasible to insert dental implants and perform an abutment surgery in patients with cancer on HDAR, without the development of MRONJ.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04741906.

U2 - 10.1007/s10006-022-01042-5

DO - 10.1007/s10006-022-01042-5

M3 - Journal article

C2 - 35084584

VL - 27

SP - 89

EP - 100

JO - Mund-, Kiefer- und Gesichtschirurgie : MKG

JF - Mund-, Kiefer- und Gesichtschirurgie : MKG

SN - 1865-1550

IS - 1

ER -